Programming of MDSC: New opportunities for targeted therapy

Keyphrases

• Tumor Immunity 100%
• T Cell Response 100%
• Targeted Therapy 100%
• Myeloid Lineage 100%
• Tumor Immunology 100%
• PMN-MDSC 100%
• G-MDSCs 100%
• Inflammation 50%
• Macrophages 50%
• Tumor 50%
• Neutrophils 50%
• Immunomodulatory 50%
• Receptor Signaling 50%
• Murine Model 50%
• Tumor Growth 50%
• Tumor Progression 50%
• Novel Therapeutics 50%
• Inducible Nitric Oxide Synthase 50%
• Small Molecule Inhibitors 50%
• Reactive Oxygen Species 50%
• Vaccination 50%
• Tumoricidal Activity 50%
• Antigen-specific T Cells 50%
• Costimulatory Molecules 50%
• Antitumor T Cells 50%
• Major Player 50%
• Inhibitor Therapy 50%
• Monocytic 50%
• Biological Therapy 50%
• Functional Phenotype 50%
• TGF-β Receptor 50%
• Myeloid-derived Suppressor Cells 50%
• Granulocytic 50%
• Immune Checkpoint Blockade 50%
• Arginase 50%
• Phenotypic Forms 50%
• Bystander T Cells 50%
• Myeloid Precursors 50%
• Paired Immunoglobulin-like Receptor B 50%

Medicine and Dentistry

• Neoplasm 100%
• Tumor Progression 100%
• Receptor 100%
• T-Cell Response 100%
• Immunosuppressive Treatment 100%
• Targeted Therapy 100%
• Macrophage 50%
• Tumor Immunity 50%
• Immunoglobulin 50%
• Neutrophil 50%
• Precursor 50%
• Upregulation 50%
• Antigen Specificity 50%
• Reactive Oxygen Species 50%
• Inducible Nitric Oxide Synthase 50%
• Biological Therapy 50%
• Myeloid-Derived Suppressor Cell 50%
• Tumor 50%
• Immune Checkpoint Blockade 50%
• Arginase 50%

Immunology and Microbiology

• Lineage 100%
• Myeloid 100%
• T Cell 66%
• Immunosuppression 66%
• Precursor 33%
• Antigen Specificity 33%
• Macrophage 33%
• Neutrophil 33%
• Intravenous Immunoglobulin 33%
• Upregulation 33%
• Nitric Oxide Synthase 33%
• Murine 33%
• Tumor Immunity 33%
• Myeloid-Derived Suppressor Cell 33%
• Immune Checkpoint Blockade 33%